Luteolin as a potential preventive and therapeutic candidate for Alzheimer's disease

Experimental Gerontology
Youngjoo Kwon

Abstract

Amyloid cascade hypothesis is the main theoretical framework describing the development of Alzheimer's disease (AD). However, most clinical trials of therapy targeting amyloid-β peptide (Aβ) are unsuccessful because AD is a complex disease involving many genetic and environmental factors. Among various factors, inflammation within the brain in particular has been implicated in the pathogenesis and progression of AD. Furthermore, it has been shown that systemic inflammation can initiate AD. Therefore, anti-inflammatory agents might be beneficial for prevention and/or treatment of AD. Many reports have indicated that luteolin, a flavone found in various foods, has preventive and therapeutic value for neurodegenerative diseases including AD. Such effect of luteolin has been linked to its ability to relieve neuroinflammation. Luteolin also has other biological functions, including antioxidant activity that may provide added benefit for prevention of AD. The exact mechanisms of inflammatory pathways involved in AD pathogenesis need to be further understood to utilize luteolin and many other available anti-inflammatory agents to prevent and treat AD. In addition, it is critical to develop better experimental models that resemble the ...Continue Reading

References

Aug 22, 2001·Lancet·A CagninR B Banati
Mar 19, 2002·American Journal of Respiratory and Critical Care Medicine·Anastasia KotanidouCharis Roussos
Mar 3, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Leon J ThalUNKNOWN Rofecoxib Protocol 078 study group
Aug 1, 2006·Lancet·Kaj BlennowHenrik Zetterberg
Nov 16, 2006·Current Pharmaceutical Design·Jeffrey-Tri NguyenYoshiaki Kiso
Apr 27, 2007·Neurology·UNKNOWN ADAPT Research GroupM Sabbagh
Apr 16, 2008·Journal of Cellular and Molecular Medicine·Kavon Rezai-ZadehJun Tan
May 21, 2008·Proceedings of the National Academy of Sciences of the United States of America·Saebyeol JangRodney W Johnson
Sep 27, 2008·Journal of Neuroinflammation·Kavon Rezai-ZadehR Douglas Shytle
Nov 29, 2008·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Gary W SmallMichael E Phelps
Jan 20, 2009·Mini Reviews in Medicinal Chemistry·Miguel López-Lázaro
Jan 12, 2010·Journal of Alzheimer's Disease : JAD·M Paul Murphy, Harry LeVine
Aug 6, 2010·The Journal of Nutrition·Saebyeol JangRodney W Johnson
Jun 3, 2011·The International Journal of Neuroscience·Li-Hong ZhuDa-xiang Lu
Jul 26, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·John C BreitnerUNKNOWN ADAPT Research Group
Jul 4, 2012·Journal of Neuroinflammation·Dimitrije KrsticIrene Knuesel
Oct 11, 2012·Neuropathology and Applied Neurobiology·C Holmes
Jan 12, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Martin PrinceCleusa P Ferri
Feb 19, 2013·Brain Research Bulletin·Yi LiuXiaoxing Yin
Apr 9, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·UNKNOWN Alzheimer's Disease Anti-inflammatory Prevention Trial Research Group
Jul 11, 2013·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Wanling WuTingting Wang
Jan 15, 2014·International Journal of Molecular Sciences·Darrell SawmillerJun Tan
Feb 15, 2014·Current Diabetes Reports·Anusha Jayaraman, Christian J Pike
Mar 20, 2014·Free Radical Biology & Medicine·Jianguo XuXinyu Lu
Mar 29, 2014·Behavioural Brain Research·Yi LiuLing Zhang
May 13, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association
May 16, 2014·Advances in Nutrition·Connie M Weaver
Jul 16, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·UNKNOWN ADAPT-FS Research Group
Sep 3, 2014·BMC Neurology·Michael A CastelloSalvador Soriano
May 27, 2015·Nature Neuroscience·Karl Herrup
Dec 27, 2015·Translational Stroke Research·Carlo CaltagironeUNKNOWN Stroke Study Group
Feb 27, 2016·Rejuvenation Research·Michael D BurtonRodney W Johnson

❮ Previous
Next ❯

Citations

Feb 3, 2018·Neurochemical Research·Zhao-Hui YaoJi-Chang Hu
Aug 9, 2019·Journal of the Science of Food and Agriculture·Pasquale MormileAlberto Ritieni
Oct 17, 2019·International Journal of Molecular Sciences·Sudip DhakalIan Macreadie
May 23, 2019·Journal of Complementary & Integrative Medicine·Samson GuennéMartin Kiendrebéogo
Jun 2, 2020·Critical Reviews in Food Science and Nutrition·Haroon KhanSeyed Mohammad Nabavi
May 7, 2019·Central Nervous System Agents in Medicinal Chemistry·Nayana Keyla Seabra de OliveiraLorane Izabel da Silva Hage-Melim
Oct 25, 2020·BioFactors·Duraisamy KempurajAsgar Zaheer
Dec 19, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Han-Rui WangNing Zhang
Feb 23, 2021·BioFactors·Alejandro DelgadoTheoharis C Theoharides
Apr 14, 2021·BioFactors·Theoharis C TheoharidesAntonios Politis
Apr 30, 2021·Expert Review of Neurotherapeutics·Marjan TalebiSaeed Samarghandian
Jan 8, 2019·International Journal of Biological Macromolecules·Rizwan Hasan KhanParveen Salahuddin
May 14, 2021·Journal of Cellular and Molecular Medicine·Man ZhangMee-Hyun Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here